Key facts

Active Substance
daclizumab
Therapeutic area
Neurology
Decision number
P/0005/2020
PIP number
EMEA-001349-PIP01-12-M03
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of multiple sclerosis
Route(s) of administration
Subcutaneous use
Contact for public enquiries

Biogen Idec Ltd

E-mail: pip.enquiries@biogen.com
Tel. +44 (0)1628 501014

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

P/0005/2020: EMA decision of 6 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for daclizumab (EMEA-001349-PIP01-12-M03)

How useful do you find this page?